Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$11700.00
-480.00 (-3.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-894.8M · quality 25.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$204.9B
P/E
124.5x
↑EV/EBITDA
19.0x
↑ROE
2.2%
↑Gross Margin
33.4%
↓Debt/Equity
1.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.7%
FCF CAGR
—
FCF margin
0.5%
FCF / Net income
0.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $143.06B · net income $1.65B · FCF $699.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $143.06B | $143.06B | $149.41B | $141.36B | $131.91B |
| Net Income | $1.65B | $1.65B | $531.4M | $-1.15B | $1.12B |
| EBITDA | $15.84B | $15.84B | $13.38B | $10.09B | $9.33B |
| EPS | 94.00 | 94.00 | 30.00 | -65.00 | 64.00 |
| Gross Margin | 33.4% | 33.4% | 35.6% | 32.1% | 34.9% |
| Operating Margin | 2.2% | 2.2% | 4.5% | 1.4% | 4.4% |
| Net Margin | 1.2% | 1.2% | 0.4% | -0.8% | 0.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.31 | 1.31 | 1.38 | 1.51 | 1.15 |
| Current Ratio | 0.53 | 0.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $699.9M | $699.9M | $-894.8M | $-11.15B | $-23.74B |
| Returns | |||||
| ROE | 2.2% | 2.2% | 0.7% | -1.6% | 1.4% |
| Valuation | |||||
| P/E | 124.47 | 124.47 | 375.00 | — | 144.22 |
| EV/EBITDA | 19.02 | 19.02 | 22.20 | 26.39 | 26.56 |
| P/B | 2.78 | 2.78 | 2.77 | 2.19 | 2.06 |
| Growth & Yield | |||||
| Revenue Growth | -4.2% | -4.2% | 5.7% | 7.2% | — |
| EPS Growth | 213.3% | 213.3% | 146.2% | -201.6% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
122.7%
EPS terminal req.
$1038.18
Spread vs growth
90.6%
5Y implied EPS CAGR
68.0%
EPS terminal req.
$1256.20
Spread vs growth
145.4%
10Y implied EPS CAGR
35.9%
EPS terminal req.
$2023.12
Spread vs growth
177.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.9%
Start / end P/E
476.3x → 124.5x
EPS bridge
30.00 → 94.00
Residual
-157.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.